Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
ACRSAclaris Therapeutics(ACRS) Zacks Investment Research·2024-03-04 23:46

Aclaris Therapeutics (ACRS) - Aclaris Therapeutics (ACRS) 是医疗组中排名第四的公司[2] - Aclaris Therapeutics 目前的Zacks Rank为2 (Buy),全年盈利预期上调15.5%[3] - ACRS 今年以来的回报率为18.1%,高于医疗股平均回报率7.5%[4] Aldeyra Therapeutics, Inc. (ALDX) - Aldeyra Therapeutics, Inc. (ALDX) 今年以来的股价上涨了20.2%[5] - Aldeyra Therapeutics, Inc. 目前的Zacks Rank为2 (Buy),全年盈利预期上调58%[6] 行业比较 - Aclaris Therapeutics 和 Aldeyra Therapeutics, Inc. 都属于医疗-药品行业,该行业今年以来平均回报率为3.1%[7] 投资建议 - 投资者应继续关注 Aclaris Therapeutics 和 Aldeyra Therapeutics, Inc.,因为它们可能会保持良好的表现[8]